Planned
IGNYTE-3 (RP1-104)
A Dose-escalation Study of RO7567132 as Single Agent and in Combination With Atezolizumab in Participants With Advanced Solid Tumors.
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Replimune
- More information : NCT06264180
- Indication :
- Internal reference number : s70853
Ongoing
EIK1001-006
A Multicenter, Randomized, Double-Blind, Active Comparator-Controlled, Adaptive Phase 2/3 Study to Evaluate the Safety and Efficacy of EIK1001 and Pembrolizumab Versus Placebo and Pembrolizumab as First-Line Therapy in Participants with Advanced Melanoma
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Eikon Therapeutics
- More information : NCT06246110
- Indication :
- Internal reference number : s69605
HERTHENA - U31402-277
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Open-label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd) in Locally Advanced or Metastatic Solid Tumors
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Daiichi Sankyo
- More information : NCT06172478
- Indication :
- Internal reference number : s68502
IMCGP100-203
Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator’s Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Immunocore
- More information : NCT05549297
- Indication :
- Internal reference number : s68071
PRISM-MEL-301 - IMC-F106C-301
A Phase 3 Randomized, Controlled Study of IMC-F106C Plus Nivolumab Versus Nivolumab Regimens in HLA-A*02: 01-Positive Participants With Previously Untreated Advanced Melanoma (PRISM-MEL-301)
- Principal investigator : Prof. Dr. O. Bechter
- Sponsor : Immunocore
- More information : NCT06112314
- Indication :
- Internal reference number : s68893